The specter of generic rivalry has long loomed around copyright’s iconic drug, Viagra, raising questions about the prospects of similar drug stakes. While first times saw substantial profits, the exclusivity end has created the path for less expensive substitutes, potentially diminishing profitability and presenting a significant risk for shareho